bution into tissues, its elimination from the body, and, ultimately, its therapeutic or toxic effects, and it is generally believed that only the unbound form of a drug interacts with its receptor to produce pharmacological effects.
This principle is the basis for understanding the pharmacoldnetic behavior and the pharmacological activity of the drugs that are avidly and extensively bound to plasma proteins at therapeutic concentrations (10) . Phenytoin and furosemide are examples of acidic drugs that are avidly and extensively bound to plasma proteins, primarily albumin;
for phenytoin, conclusive
evidence in animal models and in seizure patients shows that penetration of the drug into target tissues and clinical effects are more directly related to free concentration than to total concentration (11) (12) (13) (16, 17) . IMPDH, which is tightly linked with cell proliferation (18, 19) , catalyzes the NAD-dependent oxidation of inosine 5' -monophosphate to xanthosine 5'-monophosphate and is the key enzyme in de novo GTP biosynthesis (17, 20, 21) . Of the two isoforms of IMPDH, type I is the preponderant form in normal cells and type II, which is selectively upregulated, is the predominant form in proliferating lymphocytes (18, 22, 23) . Because MPA inhibits isoform II with a 4.8-fold lower K1 than for isoform 1 (22) after the desired pH was obtained. As the pH of the plasma samples increased from 6.0 to 8.0, the free fraction of MPA decreased from 3.6% ± 0.0% (n = 4) to 1.2% ± 0.2% (n = 4) ( 
The % free fraction of MPA (% F) was calculated as %
We also used equilibrium dialysis to evaluate the effect of temperature on MPA binding. Temperature caused only slight changes in MPA free fraction in a normal plasma pool, the free fraction values being 2.3% ± 0.6%, 1.8% ± 0.4%, and 1.5% ± 0.0% at 25, 30, and 37 #{176}C, respectively. the cells were collected in separate plastic tubes, washed with DPBS until no radioactivity was detected in the DPBS wash, centrifuged, and suspended in 100 L of fresh DPBS. Then, 100 iLL of the cell suspension was taken for radioactivity counting. The 50% MPA inhibitory concentration (IC50) for PHA stimulation was determined statistically (leastsquares fit) by PS Plot (Polysoft, Salt Lake City, UT) computer
program.
Free MPA concentration in the culture medium in each experiment was determined by ultrafiltration (see above).
Results

Comparison of ultrafiltration with equilibrium dial-
ysis. As Table 2 shows, the ultrafiltration and equilibrium dialysis methods for measuring MPA free fraction give comparable results. These data further confirm earlier reports that ultrafiltration is theoretically equivalent to equilibrium dialysis but is much simpler to perform (26, 27) These results, which are similar to those described in a recent report (29) , provide the experimental basis for selecting plasma as the sample of choice for measuring MPA concentration in pharmacokinetic and therapeutic drug monitoring studies.
MPA binding to human plasma proteins.
The results of MPA binding to HSA are shown in Fig. 1 total MPA in a solution of HSA (44 g/L; 637 mo1/L) or in a normal plasma pool. At higher total MPA concentrations (200 mgIL; 624 moI/L), the free fraction increased to 2.5%. MPA free fraction depends on the HSA concentration (Fig. 2) , as shown by the decrease in MPA free fraction, from 53.3% ± 2.0% to 0.92% ± 0.05%, as the HSA concentration increased from 0.7 g/L (10 molIL) to 69 g/L (1000 moI/L).
MPA did not bind significantly to human a1-acid glycoprotein (750 mgfL). Moreover, the MPA free fraction was essentially unchanged as total MPA concentration increased from 1 mg/L (3.12 p.mol/L) to 100 mg/L (312 .imo1/L): 96.2% ± 0.64% MPA free vs 93.0% ± 2.1%.
Effect of various drugs on MPA binding to HSA atpH 7.4. MPA binding to HSA as well as to components in normal plasma is significantly affected by its metabolite, MPAG. As MPAG concentration increased from 0 to 800 mg/L (0-1483 p.mol/L), the MPA free fraction increased from 1.33% to 4.60% in HSA solution and from 1.26% to 3.57% in a normal plasma pool.
Effect of MPA and HSA on human
IMPDH type H activity. Fig. 3 shows the results of the IMPDH activity measured in the presence of different concentrations of MPA and HSA in the TMPDH assay system. The presence of increasing amounts of HSA in the IMPDH assay system strongly increases the total MPA concentration In the absence of MPA, HSA had no effect on IMPDH catalytic activity.
Effect of MPA, in the presence or absence of HSA, on the response of human PBM to PHA stimulation.
PHA activates T lymphocytes in humans and laboratory animals (31).
MPA strongly inhibits the proliferative response of human peripheral T and B lymphocytes to mitogenic stimulation (17, 20, 32, 33) . The IC50 of MPA is 115.7 nmol/L (r = 0.98) when total MPA concentration in the culture medium is taken into consideration, and 44.4 For MPA, however, our study has shown that a standard ultrafiltration pro#{235}edure pro- (Fig. 4 ). In this case (i.e., with HSA present), only 4.1% ± 0.1% (n = 10) of MPA was in the free form. The slight inhibitory effect of HSA itself on PBM growth was taken into consideration in calculation of the final results. vides a practical, accurate, and reproducible means of measuring its free concentration.
Of all the factors that could potentially alter the binding of MPA to HSA, the concentration of HSA itself provided the most substantial effect (Fig. 2) . Thus, the MPA free fraction increased -=41-fold when the HSA concentration decreased from its physiological concentration of 600 jmol/L (41.4 g/L) to 10 mol/L (0.07 g/L). The increase in MPA free fraction was 2.2-fold when HSA decreased to 300 molJL (20.7 g/L). Many reports describe reduced drug binding in diseases associated with hypoalbuminemia, e.g., liver disease, various types of renal dysfunction, burn injuries, and malnutrition (7, 11, 35 The data in our study show that MPA is avidly and extensively bound to HSA. The observation that the in vitro binding of MPA to HSA is not altered over a wide range of concentrations of cyclosporin A, prednisone, or FK-506 suggests that in transplant patients the competition for plasma protein binding sites will not be a cause of pharmacokinetic or pharmacodynamic interaction when any of these drugs are taken concomitantly with MMF. On the other hand, MPAG at high concentrations or salicylate at high concentrations significantly increases the MPA free fraction, presumably by a competitive displacement mechanism. High concentrations of MPAG are attained in some renal-transplant patients in the early posttransplant period (39) and could, therefore, increase the MPA free fraction in these patients.
Ordinary analgesic and antipyretic doses of aspirin, on the other hand, usually produce circulating salicylate concentrations of <100 mgfL; only high doses of aspirin, such as those used for treatment of inflammatory diseases or those consumed in overdose cases, would produce the high concentrations of salicylate (>250 mg/L) that would significantly increase the MPA free fraction.
Other drugs (e.g., phenytoin, digoxin, and warfarin) do not displace MPA from its HSA binding sites even at very high concentrations.
The IC50 for inhibition of IMPDH isoform II by MPA increased 5.4-fold as the concentration of HSA in the enzyme reaction mixture increased from 0 to 50 g/L (0-724 imoI/L). Thus, as the degree of MPA binding to HSA increased and the free fraction decreased, there was a corresponding decrease in inhibition of IMPDH activity for a given total concentration of inhibitor.
Furthermore, adding 10 g/L HSA (145 LmoIIL) to the culture medium containing PHA-stimulated PBM increased the IC50 for MPA inhibition of the proliferative response by 4.8-fold. Thus in this biological system, as for the purified MPA receptor, the pharmacological effect was related more directly to free rather than total drug concentration.
Using the described ultrafiltration procedure, we currently are measuring the free MPA concentration in plasma samples of cohorts of renal-transplant patients enrolled in clinical trials of MMF. This information, together with total MPA concentration, will be used to rigorously assess the pharmacokinetic and pharmacodynamic significance of MPA free fraction. Should we find that the free MPA concentration relates better to drug effects than total concentration in patients with significantly altered binding, the described ultrafiltration method will provide a practical, reliable approach to this measurement in transplant patients.
